Cysteine and serine proteases in gastric cancer

Cancer

Volumn 76, Issue 3, 1995, Pages 367-375

  Plebani, Mario ^a   Herszènyi, Làszlò ^b,c   Cardin, Romilda ^b   Roveroni, Giovanni ^a   Carraro, Paolo ^a   Paoli, Massimo D ^d   Rugge, Massimo ^e   Grigioni, Walter F ^f   Nitti, Donato ^d   Naccarato, Remo ^b   Farinati, Fabio ^b  

^a Laboratorio Centrale ^*  (Italy)

^b Istituto di Medicina Interna di Padova   (Italy)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF PADOVA   (Italy)

^e Istituto di Anatomia Patologica   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cathepsins; enzyme linked immunosorbent assay; gastric cancer; plasminogen activator inhibitor type 1; prognosis; protease; urokinase type plasminogen activator

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; UROKINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; STOMACH CANCER; STROMA CELL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CATHEPSIN B; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRIC MUCOSA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; SERINE ENDOPEPTIDASES; STOMACH NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029051104     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950801)76:3<367::AID-CNCR2820760304>3.0.CO;2-B     Document Type: Article

References (53)

1. Matrix metalloproteins: a review
2. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation
3. Elastinolytic activity of human cathepsin L
4. Purification and properties of cathepsin B from sea urchin eggs
5. Cathepsin B and cystatins: evidence for a role in cancer progression
6. Plasminogen activators, tissue degradation and cancer
7. Cell‐associated plasminogen activation: regulation and physiological functions
8. The relevance of plasminogen activators to neoplastic growth—a review of recent literature
9. The urokinase type of plasminogen activator in cancer of digestive tract
10. Biology of tumour metastasis
11. Plasminogen activator inhibitors
12. Fibrinolytic pathways and the endothelium
13. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions
14. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas
15. Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis
16. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas
17. Urokinase‐ plasminogen activator, a new and independent prognostic marker in breast cancer
18. High levels of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in cytosolic extracts of breast carcinomas are associated with poor prognosis
19. Urokinase (uPA) and its inhibitor PAI‐1 are strong and independent prognostic factors in node‐ negative breast cancer
20. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue
21. Prognostic value of urokinase‐type plasminogen activator (UPA) and plasminogen activator inhibitors PAI‐1 and PAI‐2 in breast carcinomas
22. Content and characterisation of plasminogen activators in human lung tumors and normal lung tissue
23. Isolation and characterisation of plasminogen activators from hyperplastic and malignant prostate tissue
24. Elevated levels of urokinase‐type plasminogen activator and plasminogen activator inhibitor type 1 in malignant human brain tumors
25. Plasminogen activator secretion of human tumors in short‐term organ culture, including a comparison of primary and metastatic colon tumors
26. Plasminogen activator activity and composition in human colorectal carcinomas
27. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia: implication of urokinase in colorectal carcinogenesis
28. Localisation of urokinase‐type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans
29. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas
30. Plasminogen activators and plasminogen activator inhibitor in malignant and non‐malignant ascitic fluid
31. Plasminogen activator inhibitor 1 in human carcinoma tissues
32. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas
33. Antibodies to plasminogen activator inhibit human tumor metastasis
34. Correlation between urokinase type plasminogen activator production and the metastasising ability of two murine mammary adenocarcinomas
35. Proteinase‐like peptidase activities in malignant and non‐malignant gastric tissue
36. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings
37. Protease activities in gastric cancer tissues
38. Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining
39. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach
40. Prognostic impact of urokinase‐type plasminogen activator and its inhibitor PAI‐1 in completely resected gastric cancer
41. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues
42. Geschwülste des Magens und Duodenums
43. The two histologic main types of gastric carcinoma: Diffuse and so‐called intestinal type carcinoma: an attempt at a histo‐clinical classification
44. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐ dye binding
45. Type‐1 plasminogen activator inhibitor in human breast carcinomas
46. Tumor invasion: A consequence of destructive and compositional matrix alterations
47. Plasminogen activator inhibitor type‐1 in Lewis lung carcinoma
48. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelin cells expressing the middle T‐ oncogene
49. Gelatinase A (MMP‐2) and its mRNA detected in both neoplastic and stromal cells of tumors with different invasive and metastatic properties
50. Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis
51. Advanced gastric cancer and prognosis
52. Goseki histological grading of gastric cancer is an important predictor of outcome